The primary objectives of this study are to evaluate the effect of Elafibranor treatment compared to placebo on 1) histological improvement and 2) all-cause mortality and liver-related outcomes in patients with nonalcoholic steatohepatitis (NASH) and fibrosis.
Contact site for start date.
Please contact ClinicalResearch@sutterhealth.org about Study RESOLVE-IT.
View study details on ClinicalTrials.gov
Subjects 18-75 years of age with histologic evidence of NASH and stage 1, 2 or 3 fibrosis on liver biopsy obtained no more than 6 months before study day 1.
June 01, 2018